Geron Ends Phase 3 Study of Rytelo in Myelofibrosis Due to Futility

What happened

Geron Corp. is ending a Phase 3 study of its drug Rytelo in myelofibrosis, a bone marrow cancer, after an independent monitoring committee said the trial was unlikely to meet its main goal of overall survival.

Confirmed

Global impact / market context

Ending a late-stage trial removes a possible future revenue source for Geron and wastes money already spent on research. The failed study could make investors more cautious about the company's pipeline, which means its other experimental drugs.

Analyst inference

Geron shares were halted before the market opened, so investors could not trade on the news immediately. Rytelo is already approved for a different blood condition, lower-risk myelodysplastic syndromes with anemia, which gives the company one product with sales.

Analyst inference

What to watch

1. Geron said no new safety signals appeared in the study that change the drug's known safety profile or require additional safety monitoring. Confirmed
2. Investors may want to watch whether Geron announces new research plans or shifts spending toward Rytelo's approved use in lower-risk myelodysplastic syndromes with anemia. Proposed
3. When trading resumes, the share price reaction will show how much investors had priced in a successful myelofibrosis trial, which means expected future sales from that use. Analyst inference

Evidence

• Original source link unavailable